Cancer-Pain Remedy Wins Orphan-Drug Status

July 15, 1996

Cancer-pain remedy wins orphan-drug status
FOR IMMEDIATE RELEASE

CONTACTS:
UCMC: John Easton (312) 702-6241, jeaston@mcis.bsd.uchicago.edu
or at URLabs: William Drell, Ph.D. (619) 452-7268

Cancer-Pain Remedy Wins Orphan-Drug Status



The Food and Drug Administration has granted orphan drug status to methylnaltrexone, a medication that blocks the side effects of morphine without interfering with pain relief.

The "orphan" designation provides special tax and other potential benefits to sponsors for research attempting to develop drugs to treat rare diseases. It is designed to encourage research and testing of drugs that may be clinically useful but are not likely attract the interest of pharmaceutical companies because the costs of development and distribution may exceed anticipated revenues from sales.

"Orphan drug status is a big step toward bringing this important drug to a population of patients in need," said Michael Roizen, M.D., professor and chairman of the department of anesthesia and critical care at the University of Chicago. Roizen and colleague Joseph Foss, M.D., assistant professor of anesthesia and critical care, have done the preliminary animal and clinical testing of the drug.

UR Labs, a privately held corporation active in drug development, has been working with the University of Chicago to develop methylnaltrexone for use in patients with cancer pain. United States and international patents have been filed for many indications.

Many patients with chronic pain cannot tolerate the side effects of long-term use of opioid-based pain medications such as morphine. These side effects include nausea and severe constipation. As many as 40 percent of chronic pain patients chose to live with the pain rather than endure the side effects.

But methylnaltrexone may make morphine more manageable. Recently published studies from Roizen, Foss and colleagues Chun-Su Yuan and Jonathan Moss, also from the University of Chicago, demonstrated that it can block the side effects of opioid-based pain relievers, preventing the constipation without altering its effects on pain.

Methylnaltrexone was invented by the late University of Chicago pharmacologist Leon Goldberg, M.D., Ph.D., of the to help a friend suffering from cancer. He started with naltrexone, an established anti-addiction drug that blocks the effects of morphine.

Goldberg altered the drug slightly, so that it continued to block the effects of morphine throughout the body, preventing the nausea and constipation the morphine caused. But by attaching a methyl group to the naltrexone, he altered the molecule to prevent it from crossing the protective barrier that surrounds the brain. As a result, it did not interfere with morphine's effect on pain, which is centered in the brain.

Despite encouraging results in animal models and in early trials in human volunteers, no pharmaceutical company has yet been willing to make a long-term commitment to developing methylnaltrexone.

"The costs of developing a new drug can be astronomical," said Roizen. "For a medication targeted to only a small group of users, fewer than 200,000 people, it can be difficult for the manufacturer to recoup that investment. Orphan-drug status radically improves he odds of bringing such drugs into use."

Phase II-III trials of methylnaltrexone, which test how well the drug works and how it compares to alternative medications, will begin at the University of Chicago Hospitals Clinical Research Center and a hospice in Great Britain this year.
Back to News Release summaries.


University of Chicago

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.